EPS for GlaxoSmithKline plc (ADR) (GSK) Expected At $0.71

Postado Julho 17, 2017

Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company's stock worth $102,000 after buying an additional 753 shares during the last quarter. The firm's market cap is GBX 78.59 billion. The stock was bought at an average price of GBX 1,647 ($21.33) per share, with a total value of £1,367.01 ($1,770.74). PVH Corp (PVH) has risen 16.19% since July 11, 2016 and is uptrending. Camelot Portfolios LLC now owns 20,786 shares of the pharmaceutical company's stock valued at $876,000 after buying an additional 120 shares during the last quarter. As of the latest earnings report the EPS was $0.89 and is expected to be $2.82 for the current year with 2,443,000,000 shares outstanding.

This is a increase from GlaxoSmithKline PLC's prior periodic dividend of $0.46. this indicates a $1.93 annual dividend and a payout of of 4.58%. BNP Paribas upgraded shares of GlaxoSmithKline PLC from an "underperform" rating to a "neutral" rating and decreased their target price for the stock from $45.58 to $37.20 in a research report on Wednesday, April 5th. About 698,942 shares traded.

Analysts await GlaxoSmithKline plc (ADR) (NYSE:GSK) to report earnings on July, 26. It has underperformed by 12.44% the S&P500.

Fayez Sarofim & Co lowered its position in GlaxoSmithKline PLC (NYSE:GSK) by 4.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission.

Greylin Investment Mangement Inc, which manages about $435.83M and $416.79 million US Long portfolio, decreased its stake in Conocophillips (NYSE:COP) by 17,305 shares to 136,160 shares, valued at $6.83M in 2016Q4, according to the filing.

A number of other large investors also recently added to or reduced their stakes in the stock. Four research analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have assigned a buy rating to the company. Therefore 32% are positive. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company's stock valued at $105,000 after buying an additional 2,359 shares during the last quarter. The stock has "Neutral" rating by JP Morgan on Wednesday, April 26. BNP Paribas upgraded GlaxoSmithKline plc (ADR) (NYSE:GSK) on Wednesday, April 5 to "Neutral" rating. ValuEngine downgraded shares of GlaxoSmithKline PLC from a "buy" rating to a "hold" rating in a report on Friday, June 2nd.

Shares of GlaxoSmithKline PLC (NYSE GSK) opened at 42.21 on Tuesday. GSK's SI was 4.80 million shares in July as released by FINRA. Finally, Perigon Wealth Management LLC increased its position in shares of GlaxoSmithKline PLC by 3.3% in the fourth quarter. Investors of record on Friday, May 12th were given a $0.483 dividend. The California-based Avalon Global Asset Management Llc has invested 3.09% in the stock. Liberty Mutual Grp Asset Mgmt Inc holds 131,580 shares. $2.56M worth of UnitedHealth Group Inc (NYSE:UNH) was sold by HOOPER MICHELE J. (NYSE:V), 22 have Buy rating, 0 Sell and 5 Hold. Therefore 100% are positive.

GSK has been the subject of several recent research reports. The rating was initiated by Compass Point on Friday, April 15 with "Neutral". The company was upgraded on Wednesday, December 9 by Bank of America. The rating was maintained by Keefe Bruyette & Woods on Tuesday, December 8 with "Outperform". On Monday, October 26 the stock rating was maintained by JP Morgan with "Neutral". The rating was maintained by Shore Capital with "Buy" on Thursday, November 12. The firm's market capitalization is GBX 78.59 billion. As per Friday, July 22, the company rating was maintained by Stifel Nicolaus. The company was maintained on Monday, September 14 by RBC Capital Markets. They expect $0.09 EPS, up 50.00% or $0.03 from last year's $0.06 per share. Another trade for 125,372 shares valued at $10.75 million was sold by Sheedy William M.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.